Life Sciences Firm Advances Massive US$2.4B Market Opportunity

BioLargo's Clyra Medical Technologies presents positive clinical experiences with ViaCLYR wound irrigation solution

Mar. 19, 2026 at 12:00am

Got story updates? Submit your updates here. ›

BioLargo Inc. (BLGO:OTCQX), a cleantech and life sciences leader, announced that clinical experiences with ViaCLYR, an advanced wound irrigation solution from its subsidiary Clyra Medical Technologies, were presented at the Boswick Symposium in Maui, Hawaii. The presentation by Dr. Marcus Gitterle, a prominent figure in wound care, highlighted the solution's excellent safety, strong antimicrobial performance, and enhanced healing characteristics in challenging wound care scenarios.

Why it matters

The global market for anti-biofilm wound dressings is expected to grow from US$943.5 million in 2025 to US$2.4 billion by 2035, driven by the increasing incidence of surgical site infections, diabetic ulcers, and chronic wounds. ViaCLYR's positive clinical results position it as a promising tool in the fight against hospital-acquired infections and antibiotic resistance.

The details

Dr. Gitterle shared results from a multi-site evaluation involving about 36 cases across four wound clinics over four months. The presentation highlighted outcomes in challenging wound care scenarios, such as diabetic foot ulcers, venous leg ulcers, pressure injuries, and complex surgical wounds. Gitterle described the results as "remarkable" and "unusual," noting ViaCLYR's excellent safety, strong antimicrobial performance, and enhanced healing characteristics. Importantly, no adverse reactions were reported during the evaluation, underscoring ViaCLYR's favorable safety and tolerability profile.

  • The Boswick Symposium, where the clinical experiences were presented, took place on January 28, 2026.
  • Clyra Medical Technologies received its first commercial stocking order for ViaCLYR from Advanced Solution LLC in February 2026, marking the start of commercial distribution.

The players

BioLargo Inc.

A cleantech and life sciences leader that operates as a technology incubator, advancing its proprietary technologies through scientific validation and partnering with established organizations to scale these innovations.

Clyra Medical Technologies

A partially owned subsidiary of BioLargo that focuses on infection control and advanced wound care. The company develops and commercializes wound care solutions based on its proprietary Copper-Iodine Complex Technology.

Dr. Marcus Gitterle

A prominent figure in wound care and Regional Medical Director for Wound Care and Hyperbaric Oxygen Therapy at Christus Santa Rosa Hospital System in San Antonio, Texas.

Steve Harrison

The Chief Executive Officer of Clyra Medical Technologies.

Dennis P. Calvert

The President and CEO of BioLargo.

Got photos? Submit your photos here. ›

What they’re saying

“In our multi-site clinical experience involving approximately 36 cases across diverse wound etiologies, ViaCLYR™ demonstrated clinically significant improvements in several wound characteristics, including enhanced granulation velocity, rapid sinus tract closure, and notable drainage reduction. Patients with chronic, fibrotic wounds showed rapid transformation to highly proliferative healing wounds, characteristics I found quite unusual given the severity of underlying disease and chronicity. Importantly, we observed no adverse events in our treatment population. The tissue effects we observed are likely related not only to very effective long-duration wound cleansing and biofilm suppression, but also to the beneficial effects of copper on healing processes.”

— Dr. Marcus Gitterle, Regional Medical Director for Wound Care and Hyperbaric Oxygen Therapy at Christus Santa Rosa Hospital System

“Having an independent clinician of Dr. Gitterle's stature describe real-world performance that exceeds expectations, presented to a highly respected audience of wound care specialists, represents important validation as we continue our commercial rollout.”

— Steve Harrison, Chief Executive Officer of Clyra Medical Technologies

“Hearing clinicians describe transformative clinical outcomes (such as) wounds transitioning from chronic and fibrotic to highly proliferative in remarkably short timeframes is exactly what drives adoption in wound care. Dr. Gitterle's presentation reinforces the promise of Clyra's technology as we expand access to ViaCLYR™ and support the clinical community with evidence-based solutions.”

— Dennis P. Calvert, Chairman of Clyra and CEO of BioLargo

What’s next

Clyra Medical Technologies said it remains committed to supporting ongoing clinical evaluations and plans additional presentations and publications throughout 2026 as part of its dedication to evidence-based adoption and clinician education.

The takeaway

BioLargo's Clyra Medical Technologies is poised to capitalize on the growing US$2.4 billion market opportunity for anti-biofilm wound dressings, as its ViaCLYR solution demonstrates promising clinical results in effectively eliminating pathogens without harming human tissue, positioning it as a valuable tool in the fight against hospital-acquired infections and antibiotic resistance.